PT-141: A Central, Not Vascular, Mechanism

The short version

PT-141, known by its approved name bremelanotide, is a synthetic peptide that activates melanocortin receptors concentrated in the brain, chiefly one called MC4R. Unlike medicines that work on blood vessels, bremelanotide is studied for a central-nervous-system mechanism tied to sexual desire and arousal. It is FDA-approved as an injectable prescription medicine for a single indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Two Phase 3 trials involving more than 1,200 women showed statistically significant improvement in desire and a reduction in desire-related distress over placebo ^[13].

Everything outside that approved population and approved use — men, postmenopausal women, or performance enhancement — is off-label, unapproved, and not what the label's evidence covers. This page keeps to restrained clinical language throughout, and treats the drug's approved indication and its off-label research-chemical availability as two separate, clearly labeled subjects.

What it is

Bremelanotide is a synthetic cyclic heptapeptide — a seven-amino-acid ring — built as an analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and a lactam bridge linking the aspartate and lysine side chains. It is structurally related to melanotan II but differs in its C-terminal chemistry, which changes its receptor selectivity and pharmacokinetics. The approved US prescribing information lists a terminal half-life of roughly 2.7 hours (range 1.9-4.0 hours), a volume of distribution of 25.0 L, and clearance of 6.5 L per hour, with excretion split between urine (about 65%) and feces (about 23%) ^[15].

How it works

Bremelanotide activates central melanocortin receptors — chiefly MC4R, and to a lesser extent MC3R — concentrated in the hypothalamus and limbic system. By stimulating MC4R in hypothalamic circuits such as the medial preoptic area, it is thought to engage dopaminergic pathways that govern sexual desire and motivation. This distinguishes it mechanistically from medicines that act peripherally on vascular smooth muscle: bremelanotide's proposed site of action is in the brain's motivational circuitry, not the blood vessels of the genital tissue. A 2022 randomized, placebo-controlled crossover fMRI study in premenopausal women with HSDD found that MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain activity in response to erotic stimuli, including enhanced amygdala-insula connectivity — direct neuroimaging evidence for a central mechanism ^[12]. A 2025 study in female Syrian hamsters, however, found that neither low- nor high-dose bremelanotide changed melanocortin-receptor expression in the brain's reward circuitry, and that it did not enhance the rewarding aspect of sexual interaction in that model — a nuanced finding suggesting the drug's action on desire and on reward may be separable ^[11].

What the research shows

Mechanistic neuroimaging (2022). In a randomized, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD, MC4R agonism significantly increased sexual desire for up to 24 hours and produced measurable changes in brain processing of erotic stimuli ^[12].

Phase 3 efficacy trials (2019). Two identical Phase 3 randomized controlled trials — the RECONNECT program, enrolling 1,267 premenopausal women with HSDD — found that bremelanotide 1.75 mg subcutaneous, taken as needed, produced a statistically significant improvement in sexual desire and a statistically significant reduction in desire-related distress versus placebo over 24 weeks, meeting both coprimary endpoints in both trials. The most common adverse events were nausea, flushing, and headache ^[13].

Long-term open-label extension (2019). In the 52-week open-label extension of RECONNECT, enrolling 684 women, no new safety signals emerged and desire improvements were sustained. The most common drug-related adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) ^[14].

US prescribing information. The approved label specifies the HSDD indication, the 1.75 mg as-needed subcutaneous dose (maximum one dose per 24 hours, no more than eight doses per month), full pharmacokinetic parameters, and a warning on transient blood-pressure increase that contraindicates use in uncontrolled hypertension or known cardiovascular disease ^[15].

Reward-circuit study (2025). In female Syrian hamsters, neither dose of bremelanotide changed melanocortin-receptor expression in the mesolimbic dopamine reward system, and it did not enhance sexual reward as measured by conditioned place preference — a negative finding that helps separate the drug's desire-related effect from any effect on reward processing ^[11].

Reported effects, cautions & safety

The following is anecdotal, not clinical evidence — compiled from published patient-review platforms, peptide-user forums, and telehealth-clinic accounts. It is not drawn from controlled trials and carries no clinical weight beyond what people report.

The most commonly described benefit, consistent with the drug's studied mechanism, is a felt increase in sexual desire that people describe as starting mentally rather than physically. Greater physical arousal and sensitivity are frequently reported, along with easier or more intense pleasure for some users, and — in the off-label male research-use community — spontaneous erections described as arriving from desire rather than direct stimulation. Some describe a stronger sense of emotional closeness during intimacy, and many note a delayed onset (roughly half an hour to a few hours) with effects that can last well into the following day. A real and recurring report, described honestly across review platforms, is that some users notice no effect at all on desire or arousal while still experiencing side effects.

On the adverse side, nausea is by far the most common complaint and the leading reason people stop, typically starting within about half an hour, worst with the first dose, and easing with continued use. Flushing and warmth, headache, and injection-site irritation are all frequently reported. Tingling or heightened skin sensitivity, and fatigue or drowsiness for several hours, are reported occasionally. With frequent or repeated dosing, some users report darkening of skin, gums, or moles that does not always fully fade after stopping.

The published safety cautions track closely with the anecdotal picture but add regulatory and mechanistic detail. Bremelanotide is approved only for premenopausal women with HSDD — use in men, postmenopausal women, or for performance enhancement is off-label and outside the studied population ^[13][14][15]. It causes a transient blood-pressure rise with a matching small drop in heart rate, and the label warns against use in people with uncontrolled hypertension or known cardiovascular disease ^[15]. Nausea affects roughly 40% of users over long-term use and is the leading cause of discontinuation ^[13][14]. Because bremelanotide also activates pigment-producing receptors in skin, repeated frequent dosing can cause darkening of the face, gums, and breasts that may not fully reverse ^[15]. The NIH LiverTox monograph notes a signal for mild liver-enzyme changes and, rarely, clinically apparent liver injury. Material sold outside the pharmaceutical system as "PT-141 research chemical" has no verified identity, purity, or concentration, and forensic testing of black-market melanocortin peptides has confirmed unregulated product circulates. Because the same MC4R pathway also governs appetite, high-frequency dosing has reduced food intake and body weight in research settings — a pharmacological side effect, not an approved or recommended use. Use during pregnancy or breastfeeding is unsupported by any data.

Where it fits on the shelf

PT-141 is the one compound on this shelf with a full FDA approval, a defined dose, and a defined population behind it — a different evidentiary category entirely from BPC-157's three human pilot reports or NAD+'s marker-versus-outcome gap. That approval, though, is narrower than casual online discussion often implies: it covers one diagnosis in one population, and everything else is unstudied by the same standard. GHK-Cu is the other compound here with meaningful human trial data, though in an entirely different domain — skin, not sexual health. See all four side by side on the comparison page.